Literature DB >> 11802090

Pharmacokinetic and other drug interactions in patients with AIDS.

A Dasgupta1, P C Okhuysen.   

Abstract

A variety of medications are used in treating patients infected with the human immunodeficiency virus (HIV). These medications are used to control viremia and to prevent and treat opportunistic infections. An individual is often required to take numerous drugs at the same time and thus clinicians are confronted with potential drug interactions, some of which are significant. Three different groups of anti-HIV drugs are used to treat patients. These groups include nucleoside reverse transcription inhibitors, non-nucleoside reverse transcription inhibitors, and protease inhibitors. This article reviews the most relevant drug interactions that occur during the treatment of HIV-infected patients with traditional and also alternative drugs. The role of therapeutic drug monitoring in the routine management of HIV-infected patients is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11802090     DOI: 10.1097/00007691-200112000-00001

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

Review 1.  Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis?

Authors:  Offie Porat Soldin; Ronald J Elin; Steven J Soldin
Journal:  Arch Pathol Lab Med       Date:  2003-01       Impact factor: 5.534

2.  No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.

Authors:  Jürgen Burhenne; Anne-Kathrin Matthée; Ivana Pasáková; Claudia Röder; Tilman Heinrich; Walter Emil Haefeli; Gerd Mikus; Johanna Weiss
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

3.  Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

Authors:  Leah Tong; Truc K Phan; Kelly L Robinson; Darius Babusis; Robert Strab; Siddhartha Bhoopathy; Ismael J Hidalgo; Gerald R Rhodes; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

4.  Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.

Authors:  Salvador E Cabrera; Dolores Santos; María P Valverde; Alfonso Domínguez-Gil; Francisco González; Guillermo Luna; María J García
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

5.  Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir.

Authors:  Adrian S Ray; Loren Olson; Arnold Fridland
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 6.  Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.

Authors:  Jeffrey S Barrett; Line Labbé; Marc Pfister
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.